New cocktail of drugs shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT06967155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of four drugs—irinotecan, dabrafenib, trametinib, and either cetuximab or panitumumab—as a second-line treatment for people with metastatic colorectal cancer that has a BRAF V600E mutation. The study aims to see how well this drug mix shrinks tumors and controls the disease. About 23 participants will be followed for up to three years to monitor response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Irinotecan, dabrafenib, trametinib, and cetuximab or panitumumab
- What this could lead to
- If successful, this could offer a new second-line treatment option for people with a specific type of advanced colorectal cancer that has a BRAF mutation.
- What could go wrong
- This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drug combination can cause significant side effects, and it is not yet known if it will improve survival compared to existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BRAF V600E-MUTATED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Blokhin's Russian Cancer Research Center
Moscow, Moscow, 115478, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a simple text message transform cancer care?
- Can modern Radiotherapy's late effects be predicted?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva